Werewolf Therapeutics (HOWL) Stock Forecast, Price Target & Predictions
HOWL Stock Forecast
Werewolf Therapeutics stock forecast is as follows: an average price target of $12.00 (represents a 494.06% upside from HOWL’s last price of $2.02) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
HOWL Price Target
The average price target for Werewolf Therapeutics (HOWL) is $12.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential 494.06% upside from HOWL's last price of $2.02.
HOWL Analyst Ratings
According to 4 Wall Street analysts, Werewolf Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for HOWL stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Werewolf Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 03, 2024 | Reni Benjamin | JMP Securities | $12.00 | $6.06 | 98.02% | 494.06% |
The latest Werewolf Therapeutics stock forecast, released on Apr 03, 2024 by Reni Benjamin from JMP Securities, set a price target of $12.00, which represents a 98.02% increase from the stock price at the time of the forecast ($6.06), and a 494.06% increase from HOWL last price ($2.02).
Werewolf Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $12.00 |
| Last Closing Price | $2.02 | $2.02 | $2.02 |
| Upside/Downside | -100.00% | -100.00% | 494.06% |
In the current month, the average price target of Werewolf Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Werewolf Therapeutics's last price of $2.02. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 26, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jun 26, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Jun 26, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 06, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| May 06, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Apr 03, 2024 | JMP Securities | Market Outperform | Outperform | Initialise |
| Apr 03, 2024 | JMP Securities | - | Market Outperform | Initialise |
| Aug 24, 2023 | Wedbush | - | Outperform | Initialise |
| May 11, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Apr 26, 2022 | Zacks Investment Research | - | Hold | Upgrade |
Werewolf Therapeutics's last stock rating was published by H.C. Wainwright on Jun 26, 2024. The company gave HOWL a "Underperform" rating, the same as its previous rate.
Werewolf Therapeutics Financial Forecast
Werewolf Therapeutics Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $5.90M | $8.08M | $4.46M | $7.28M | $4.97M | $4.15M |
| Avg Forecast | $1.37M | $1.36M | $1.34M | $1.32M | $1.30M | $1.29M | $1.27M | $1.25M | $1.24M | $1.22M | $1.20M | $1.19M | $1.15M | $709.32K | $841.78K | $1.46M | $1.94M | $1.59M | $3.15M | $2.03M | $2.07M | $3.05M | $5.00M |
| High Forecast | $1.37M | $1.36M | $1.34M | $1.32M | $1.30M | $1.29M | $1.27M | $1.25M | $1.24M | $1.22M | $1.20M | $1.19M | $1.15M | $709.32K | $841.78K | $1.46M | $3.53M | $1.59M | $3.15M | $2.03M | $2.07M | $3.05M | $5.00M |
| Low Forecast | $1.37M | $1.36M | $1.34M | $1.32M | $1.30M | $1.29M | $1.27M | $1.25M | $1.24M | $1.22M | $1.20M | $1.19M | $1.15M | $709.32K | $841.78K | $1.46M | $353.42K | $1.59M | $3.15M | $2.03M | $2.07M | $3.05M | $5.00M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.71% | 2.57% | 2.20% | 3.51% | 1.63% | 0.83% |
Werewolf Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $1.94M, with a low forecast of $353.42K, and a high forecast of $3.53M. HOWL's average Quarter revenue forecast represents a -67.04% decrease compared to the company's last Quarter revenue of $5.90M (Sep 23).
Werewolf Therapeutics EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-9.25M | $-5.10M | $-12.22M | $-13.18M | $-12.13M | $-14.79M |
| Avg Forecast | $274.79K | $271.20K | $267.66K | $264.17K | $260.72K | $257.31K | $253.95K | $250.63K | $247.36K | $244.13K | $240.94K | $237.79K | $229.42K | $141.86K | $168.36K | $291.49K | $388.76K | $318.20K | $630.00K | $406.67K | $414.40K | $610.00K | $1000.00K |
| High Forecast | $274.79K | $271.20K | $267.66K | $264.17K | $260.72K | $257.31K | $253.95K | $250.63K | $247.36K | $244.13K | $240.94K | $237.79K | $229.42K | $141.86K | $168.36K | $291.49K | $706.83K | $318.20K | $630.00K | $406.67K | $414.40K | $610.00K | $1000.00K |
| Low Forecast | $274.79K | $271.20K | $267.66K | $264.17K | $260.72K | $257.31K | $253.95K | $250.63K | $247.36K | $244.13K | $240.94K | $237.79K | $229.42K | $141.86K | $168.36K | $291.49K | $70.68K | $318.20K | $630.00K | $406.67K | $414.40K | $610.00K | $1000.00K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -29.07% | -8.09% | -30.06% | -31.80% | -19.89% | -14.79% |
undefined analysts predict HOWL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Werewolf Therapeutics's previous annual EBITDA (undefined) of $NaN.
Werewolf Therapeutics Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-8.29M | $-5.10M | $-11.32M | $-10.68M | $-11.35M | $-14.22M |
| Avg Forecast | $-24.09M | $-20.95M | $-18.32M | $-18.79M | $-16.90M | $-15.69M | $-14.58M | $-13.64M | $-28.04M | $-30.18M | $-29.98M | $-30.63M | $-19.51M | $-17.63M | $-16.37M | $-14.88M | $-18.45M | $-16.80M | $-18.37M | $-20.89M | $-23.76M | $-25.57M | $-12.84M |
| High Forecast | $-24.09M | $-20.95M | $-18.32M | $-18.79M | $-16.90M | $-15.69M | $-14.58M | $-13.64M | $-28.04M | $-30.18M | $-29.98M | $-30.63M | $-19.51M | $-15.48M | $-16.37M | $-14.88M | $-12.44M | $-16.80M | $-18.37M | $-20.89M | $-23.76M | $-25.57M | $-12.84M |
| Low Forecast | $-24.09M | $-20.95M | $-18.32M | $-18.79M | $-16.90M | $-15.69M | $-14.58M | $-13.64M | $-28.04M | $-30.18M | $-29.98M | $-30.63M | $-19.51M | $-19.35M | $-16.37M | $-14.88M | $-22.74M | $-16.80M | $-18.37M | $-20.89M | $-23.76M | $-25.57M | $-12.84M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.49% | 0.28% | 0.54% | 0.45% | 0.44% | 1.11% |
Werewolf Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. HOWL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Werewolf Therapeutics SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.31M | $4.57M | $4.98M | $4.60M | $4.44M | $5.23M |
| Avg Forecast | $1.37M | $1.35M | $1.34M | $1.32M | $1.30M | $1.28M | $1.27M | $1.25M | $1.23M | $1.22M | $1.20M | $1.19M | $1.14M | $707.56K | $839.70K | $1.45M | $1.94M | $1.59M | $3.14M | $2.03M | $2.07M | $3.04M | $4.99M |
| High Forecast | $1.37M | $1.35M | $1.34M | $1.32M | $1.30M | $1.28M | $1.27M | $1.25M | $1.23M | $1.22M | $1.20M | $1.19M | $1.14M | $707.56K | $839.70K | $1.45M | $3.53M | $1.59M | $3.14M | $2.03M | $2.07M | $3.04M | $4.99M |
| Low Forecast | $1.37M | $1.35M | $1.34M | $1.32M | $1.30M | $1.28M | $1.27M | $1.25M | $1.23M | $1.22M | $1.20M | $1.19M | $1.14M | $707.56K | $839.70K | $1.45M | $352.54K | $1.59M | $3.14M | $2.03M | $2.07M | $3.04M | $4.99M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.72% | 1.45% | 2.46% | 2.23% | 1.46% | 1.05% |
Werewolf Therapeutics's average Quarter SG&A projection for Dec 23 is $1.94M, based on 3 Wall Street analysts, with a range of $352.54K to $3.53M. The forecast indicates a -55.01% fall compared to HOWL last annual SG&A of $4.31M (Sep 23).
Werewolf Therapeutics EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.23 | $-0.14 | $-0.33 | $-0.35 | $-0.38 | $-0.52 |
| Avg Forecast | $-0.55 | $-0.48 | $-0.42 | $-0.43 | $-0.39 | $-0.36 | $-0.33 | $-0.31 | $-0.64 | $-0.69 | $-0.69 | $-0.70 | $-0.45 | $-0.41 | $-0.38 | $-0.34 | $-0.42 | $-0.39 | $-0.42 | $-0.48 | $-0.55 | $-0.59 | $-0.29 |
| High Forecast | $-0.55 | $-0.48 | $-0.42 | $-0.43 | $-0.39 | $-0.36 | $-0.33 | $-0.31 | $-0.64 | $-0.69 | $-0.69 | $-0.70 | $-0.45 | $-0.36 | $-0.38 | $-0.34 | $-0.29 | $-0.39 | $-0.42 | $-0.48 | $-0.55 | $-0.59 | $-0.29 |
| Low Forecast | $-0.55 | $-0.48 | $-0.42 | $-0.43 | $-0.39 | $-0.36 | $-0.33 | $-0.31 | $-0.64 | $-0.69 | $-0.69 | $-0.70 | $-0.45 | $-0.44 | $-0.38 | $-0.34 | $-0.52 | $-0.39 | $-0.42 | $-0.48 | $-0.55 | $-0.59 | $-0.29 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.60% | 0.33% | 0.69% | 0.64% | 0.65% | 1.76% |
According to undefined Wall Street analysts, Werewolf Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to HOWL previous annual EPS of $NaN (undefined).
Werewolf Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACET | Adicet Bio | $1.48 | $32.50 | 2095.95% | Buy |
| PASG | Passage Bio | $0.70 | $6.00 | 757.14% | Buy |
| VOR | Vor Biopharma | $0.91 | $6.00 | 559.34% | Buy |
| HOWL | Werewolf Therapeutics | $2.02 | $12.00 | 494.06% | Buy |
| MOLN | Molecular Partners | $5.51 | $29.00 | 426.32% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.80 | $6.00 | 233.33% | Buy |
| EWTX | Edgewise Therapeutics | $17.52 | $48.00 | 173.97% | Buy |
| ACRV | Acrivon Therapeutics | $8.08 | $21.50 | 166.09% | Buy |
| STOK | Stoke Therapeutics | $14.70 | $33.33 | 126.73% | Buy |
| CCCC | C4 Therapeutics | $5.40 | $11.33 | 109.81% | Hold |
| CELC | Celcuity | $15.06 | $31.50 | 109.16% | Buy |
| DSGN | Design Therapeutics | $4.67 | $9.67 | 107.07% | Buy |
| CGEM | Cullinan Oncology | $17.98 | $32.00 | 77.98% | Buy |
| ELYM | Eliem Therapeutics | $7.39 | $13.00 | 75.91% | Buy |
| THRD | Third Harmonic Bio | $12.00 | $16.15 | 34.58% | Buy |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
HOWL Forecast FAQ
Is Werewolf Therapeutics a good buy?
Yes, according to 4 Wall Street analysts, Werewolf Therapeutics (HOWL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of HOWL's total ratings.
What is HOWL's price target?
Werewolf Therapeutics (HOWL) average price target is $12 with a range of $12 to $12, implying a 494.06% from its last price of $2.02. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Werewolf Therapeutics stock go up soon?
According to Wall Street analysts' prediction for HOWL stock, the company can go up by 494.06% (from the last price of $2.02 to the average price target of $12), up by 494.06% based on the highest stock price target, and up by 494.06% based on the lowest stock price target.
Can Werewolf Therapeutics stock reach $3?
HOWL's average twelve months analyst stock price target of $12 supports the claim that Werewolf Therapeutics can reach $3 in the near future.
What are Werewolf Therapeutics's analysts' financial forecasts?
Werewolf Therapeutics's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $5.11M (high $5.11M, low $5.11M), average EBITDA is $1.02M (high $1.02M, low $1.02M), average net income is $-60.804M (high $-60.804M, low $-60.804M), average SG&A $5.1M (high $5.1M, low $5.1M), and average EPS is $-1.397 (high $-1.397, low $-1.397). HOWL's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $5.39M (high $5.39M, low $5.39M), average EBITDA is $1.08M (high $1.08M, low $1.08M), average net income is $-82.151M (high $-82.151M, low $-82.151M), average SG&A $5.38M (high $5.38M, low $5.38M), and average EPS is $-1.888 (high $-1.888, low $-1.888).
Did the HOWL's actual financial results beat the analysts' financial forecasts?
Based on Werewolf Therapeutics's last annual report (Dec 2023), the company's revenue was $19.94M, beating the average analysts forecast of $8.72M by 128.75%. Apple's EBITDA was $-37.368M, missing the average prediction of $1.74M by -2243.13%. The company's net income was $-37.368M, missing the average estimation of $-74.509M by -49.85%. Apple's SG&A was $18.67M, beating the average forecast of $8.7M by 114.68%. Lastly, the company's EPS was $-0.001, missing the average prediction of $-1.712 by -99.94%. In terms of the last quarterly report (Sep 2023), Werewolf Therapeutics's revenue was $5.9M, beating the average analysts' forecast of $1.59M by 270.65%. The company's EBITDA was $-9.251M, missing the average prediction of $318.2K by -3007.30%. Werewolf Therapeutics's net income was $-8.285M, missing the average estimation of $-16.799M by -50.68%. The company's SG&A was $4.31M, beating the average forecast of $1.59M by 171.57%. Lastly, the company's EPS was $-0.23, missing the average prediction of $-0.386 by -40.41%